CLINICAL TRIALS PROFILE FOR CARBOPROST TROMETHAMINE
✉ Email this page to a colleague
All Clinical Trials for carboprost tromethamine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00891150 ↗ | Oxytocin to Decrease Blood Loss During Cesarean Section | Completed | American University of Beirut Medical Center | N/A | 2012-07-01 | The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed. |
| NCT02722356 ↗ | Outcomes After the Implementation of a New Oxytocin Protocol | Completed | C.R.Darnall Army Medical Center | N/A | 2016-04-01 | The proposed study is a prospective, randomized, active control, open label study. One hundred sixty subjects undergoing elective cesarean section will be randomly assigned to one of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group. The oxytocin protocol group will receive oxytocin boluses along with a regulated infusion according to a stepwise algorithm following delivery of the placenta. The standard practice group will receive oxytocin via a free flowing ("wide-open") infusion with a concentration of 30 IU per 500 mL of 0.9% normal saline following the delivery of the placenta. Primary outcomes include uterine tone (adequate or inadequate) as assessed by the surgeon, amount of time required to establish adequate uterine tone following the delivery of the infant, total dose of oxytocin required to establish adequate uterine tone, and total calculated blood loss based on pre-operative and post-operative hematocrit concentrations. Secondary outcomes include total estimated blood loss as agreed upon by the surgeon and the anesthesia provider, use of additional uterotonic drugs, mean arterial pressure, and incidence of oxytocin side effects (nausea, chest tightness/pain, and ST-segment changes). |
| NCT05518812 ↗ | Carboprost (Hemabate) for Fibroid Resection | Recruiting | Northwestern University | Early Phase 1 | 2022-07-12 | The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for carboprost tromethamine
Condition Name
Clinical Trial Locations for carboprost tromethamine
Trials by Country
Clinical Trial Progress for carboprost tromethamine
Clinical Trial Phase
Clinical Trial Sponsors for carboprost tromethamine
Sponsor Name
